SCHEMBL17777908

SCHEMBL17777908

CCOC(=O)Cc1nn(Cc2ccc(OC)cc2)c(-c2ccc(F)cc2)c1C(C)(C)CNC(=O)OC(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ASIC1 P78348 1/20 0.37
MAPT P10636 3/20 0.36
ALDH1A1 P00352 2/20 0.36
KMT2A Q03164 6/20 0.35
KLK7 P49862 1/20 0.35
MEN1 O00255 4/20 0.35
LMNA P02545 1/20 0.35
GLA P06280 1/20 0.35
MKNK2 Q9HBH9 1/20 0.35
CACNA1G O43497 1/20 0.35
THRB P10828 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
KCNK3 O14649 1/20 0.34
KDM4E B2RXH2 1/20 0.34
RAB9A P51151 1/20 0.34
CTSL P07711 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17777764 0.87 PTGDR2 (0.42) MAPTALDH1A1KMT2AMEN1GLA
SCHEMBL17777971 0.86 KCNK3 (0.39) ASIC1MAPTALDH1A1KMT2AKLK7
SCHEMBL21451580 0.85 ASIC1 (0.37) ASIC1MAPTALDH1A1KMT2AMEN1
SCHEMBL17777810 0.82 ASIC1 (0.36) ASIC1MAPTALDH1A1KMT2AMEN1
SCHEMBL17777923 0.82 ASIC1 (0.40) ASIC1MAPTALDH1A1KMT2AKLK7
SCHEMBL19711705 0.79 KCNK3 (0.40) ASIC1MAPTALDH1A1KMT2AMEN1
SCHEMBL19702820 0.77 PTGDR2 (0.41) ALDH1A1KMT2AKLK7MEN1LMNA
SCHEMBL17777930 0.77 KCNK3 (0.38) ASIC1MAPTALDH1A1KMT2AMEN1
SCHEMBL20575340 0.76 AKR1C3 (0.36) ALDH1A1KLK7LMNAPTGDR2
SCHEMBL25632913 0.75 KCNK3 (0.37) ASIC1MAPTALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183247-A1 FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE AKARNA THERAPEUTICS LTD (GB) 2023-06-15 US disclosed
US-20170355699-A1 FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE ABBVIE INC. 2017-12-14 US disclosed
WO-2016081918-A1 FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE AKARNA THERAPEUTICS, LTD. (GB) 2016-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355699-A1 FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE VHL, BRDT, PAICS ASIC1 4848/4885MAPT 982/4885ALDH1A1 1592/4885
US-20230183247-A1 FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE VHL, BRDT, PAICS ASIC1 4848/4885MAPT 982/4885ALDH1A1 1592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.